Individualization of dose prescription based on normal-tissue dose-volume and radiosensitivity data.

[1]  B Sanchez-Nieto,et al.  BIOPLAN: software for the biological evaluation of. Radiotherapy treatment plans. , 2000, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[2]  M. Zelefsky,et al.  Long term tolerance of high dose three‐dimensional conformal radiotherapy in patients with localized prostate carcinoma , 1999, Cancer.

[3]  A. Nahum,et al.  The delta-TCP concept: a clinically useful measure of tumor control probability. , 1999, International journal of radiation oncology, biology, physics.

[4]  D. Dearnaley,et al.  Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial , 1999, The Lancet.

[5]  S. Fosså,et al.  Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy. , 1999, International journal of radiation oncology, biology, physics.

[6]  R. T. Ten Haken,et al.  Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Gras,et al.  Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. , 1998, International journal of radiation oncology, biology, physics.

[8]  S. Tucker,et al.  Individualization of radiotherapy dose prescriptions by means of an in vitro radiosensitivity assay. , 1998, Radiotherapy and Oncology.

[9]  J L Bedford,et al.  A digital method for computing target margins in radiotherapy. , 1998, Medical physics.

[10]  A. Niemierko,et al.  Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  A. D'Amico,et al.  Calculated prostate carcinoma volume , 1998, Cancer.

[12]  Chantal Ginestet,et al.  Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment , 1997 .

[13]  S. Bentzen,et al.  Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  S. Tucker,et al.  How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity? , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  J. Yarnold,et al.  The relationship between cellular radiation sensitivity and tissue response may provide the basis for individualising radiotherapy schedules , 1994 .

[16]  R K Ten Haken,et al.  Use of Veff and iso-NTCP in the implementation of dose escalation protocols. , 1993, International journal of radiation oncology, biology, physics.

[17]  M. Kessler,et al.  Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Fowler.  The volume effect in radiotherapy. , 1993 .

[19]  S Webb,et al.  A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. , 1993, Physics in medicine and biology.

[20]  M. Goitein,et al.  Fitting of normal tissue tolerance data to an analytic function. , 1991, International journal of radiation oncology, biology, physics.

[21]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[22]  M Goitein,et al.  Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  C. Burman,et al.  Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. , 1989, International journal of radiation oncology, biology, physics.

[24]  J H Hendry,et al.  The modelled benefits of individualizing radiotherapy patients' dose using cellular radiosensitivity assays with inherent variability. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  D P Dearnaley,et al.  Comparison of 2D and 3D algorithms for adding a margin to the gross tumor volume in the conformal radiotherapy planning of prostate cancer. , 1998, International journal of radiation oncology, biology, physics.

[26]  A. Nahum,et al.  Normal-tissue effects in radiotherapy: physics meets biology. Report on a workshop held at Hartsfield Manor, Betchworth, Surrey, UK, 14-16 July 1997. , 1998, International journal of radiation biology.

[27]  C. Mcginn,et al.  70 A phase trial of chemoembolization with mitomycin C following hepatic arterial fluorodeoxyuridine/leucovorin and whole liver radiotherapy for patients with intrahepatic malignancies , 1997 .

[28]  A. D'Amico,et al.  Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy. , 1996, International journal of radiation oncology, biology, physics.

[29]  A. Niemierko,et al.  Modeling of normal tissue response to radiation: the critical volume model. , 1993, International journal of radiation oncology, biology, physics.